New registry tracks inflammatory breast cancer to improve understanding

NCT ID NCT06966050

Recruiting now Knowledge-focused Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Nov 06, 2025 · Last updated May 22, 2026 · Updated 22 times

Summary

This study gathers information from 200 people with stage III or IV inflammatory breast cancer (IBC) who have had or plan to have a blood test called Signatera to look for leftover cancer cells (MRD). Researchers will also ask participants about their quality of life using a standard questionnaire. The goal is to learn more about how IBC affects patients and how MRD testing relates to their outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

BREAST CANCER